{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-050307","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.346246+00:00","generated_at":"2026-06-03T13:14:57.729340+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Theriva Biologics reports positive Phase 1 data for VCN-01 in pediatric retinoblastoma and exclusive license from SJD","bullets":["Phase 1 trial of intravitreal VCN-01 in 9 evaluable patients with refractory retinoblastoma determined positive by Monitoring Committee.","Safety: no dose-limiting toxicities; most adverse events Grade 1 or 2; no Grade 3+ ocular or systemic toxicities.","Antitumor activity: 4 patients had unequivocal improvement in vitreous seed density; eye enucleation avoided in 3 patients (1 retained eye after 4 years).","Theriva will receive exclusive worldwide license and related patents from Sant Joan de Déu-Barcelona Children's Hospital for advanced retinoblastoma treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-050307","json":"https://secwatch.observer/filing/0001104659-24-050307.json","markdown":"https://secwatch.observer/filing/0001104659-24-050307.md","text":"https://secwatch.observer/filing/0001104659-24-050307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924050307/0001104659-24-050307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924050307/tm2412300d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T13:14:57.729340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}